Strepsils Menthol 1.2mg/0.6mg Lozenges

For a full list of excipients, see section 6.1

White to pale yellow coloured lozenge with a characteristic taste of cool mint and the Strepsils brand icon intagliated on both sides

For the symptomatic relief of mouth and throat infections.

Posology

Use the lowest dose for the shortest duration necessary to relieve symptoms.

Adults: One lozenge to be dissolved slowly in the mouth every 2-3 hours up to a maximum of 12 lozenges in 24 hours.

Children over 12 years: One lozenge to be dissolved slowly in the mouth every 2-3 hours up to a maximum of 8 lozenges in 24 hours.

Elderly: There is no need for dosage reduction in the elderly.

Children under 12 years:

Not suitable for children under 12 years.

Method of administration

For oral administration. To be dissolved slowly in the mouth.

Hypersensitivity to any of the ingredients.

If symptoms persist, have not improved, or have worsened after 3 days, consult a doctor or health care professional.

Patients with rare hereditary problems of fructose intolerance, glucose-glalctose malabsorption or sucrose-isomaltose insufficiency should not take this medicine.

No clinically significant interactions are known.

The safety of Strepsils Menthol 1.2mg/0.6mg Lozenges has not been established, therefore not recommended.

Pregnancy

There are no or limited amount of data from the use of amylmetacresol, 2,4-dichlorbenzyl alcohol and levomenthol.

Breast-feeding

It is unknown whether 2,4-dichlorobenzyl alcohol, amylmetacresol, levomenthol or metabolites are excreted in human milk. A risk to the newborns / infants cannot be excluded.

Fertility

No data are available regarding the effects on fertility.

No or negligible influence on the ability to drive and use machines.

The list of the following adverse effects relates to those experienced with 2,4-dichlorobenzyl alcohol and amylmetacresol at OTC doses, in short term use.

Adverse events which have been associated with 2,4-dichlorobenzyl alcohol and amylmetacresol are given below, tabulated by system organ class and frequency. Frequencies are defined as: Very common (≥1/10); Common (≥1/100 and <1/10); Uncommon (≥1/1000 and <1/100); Rare (≥1/10,000 and <1/1000); Very rare (<1/10,000); Not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.

^a2,4-dichlorobenzyl alcohol ^bamylmetacresol

¹ Hypersensitivity reactions may include rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue that could affect breathing.

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Overdose should not present a problem other than gastrointestinal discomfort. Treatment should be symptomatic.

Pharmacotherapeutic group: Throat Preparations; Antiseptics; ATC Code: R02AA03 Dichlorobenzyl alcohol.

2,4-Dichlorobenzyl alcohol and amylmetacresol have antiseptic properties.

Pharmacokinetically the active ingredients, when present in a dosage form such as a lozenge, will exert their desired effect locally on the oropharynx.

There are no preclinical data of relevance to the prescriber, which are additional to that included in other sections of the SPC.

Xylitol

Cool Mint Sensation Flavour (contains propylene glycol).

Levomenthol

Spearmint

Eucalyptus oil

Liquid Sucrose

Liquid Glucose

Not applicable.

36 months for lozenges packed in blister strips within a carton.

Do not store above 25°C.

A blister push-through pack consisting of 15 or 20µm hard temper aluminium foil heat-sealed to a 250µm PVC/40gms PVDC blister.

The tray contains an appropriate number of lozenges to give pack sizes of 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 40, 44, 48 and 720 lozenges in a cardboard carton or a flow wrap composed of PET/aluminium foil/polyethylene

A blister push-through pack consisting of 15 or 20µm hard temper aluminium foil heat-sealed to a 250µm PVC/40gms PVDC blister. The tray contains an appropriate number of lozenges to give a pack size of 8 lozenges in a wrap around cardboard carton with tamper-evident seal.

An injection moulded white pigmented polypropylene tube with an injection moulded white polyethylene cap (containing white silica gel that is sealed with a white cardboard disc).

The tube contains 10 lozenges.

20 lozenges consisting of a bundled pack of 2 tubes of 10 lozenges each.

Not all pack sizes may be marketed.

Not applicable.

Reckitt Benckiser Healthcare (UK) Ltd

Slough

SL1 3UH

PL 00063/0469

11/02/2010

18/05/2020